Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Acrivon Therapeutics, Inc. announced the advancement of ACR-2316, a WEE1/PKMYT1 inhibitor, into the randomized dose expansion portion of its Phase 1/2 study. The decision follows observed clinical activity and a favorable safety profile during dose escalation, including durable responses in heavily pretreated lung cancer …